+357 96 030922
info@marketpublishers.com

Global Small Molecule Targeted Cancer Therapy Market Size study, by Type (Small Molecule Drug Conjugates, Small Molecules (Small Molecule Cyclin-Dependent Kinase Inhibitor, Small Molecule Proteasome Inhibitor, Small Molecule Tyrosine Kinase Inhibitor)), by Monoclonal Antibodies (Fully Human Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody) and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G2AF616621B0EN.html
Date: May 2025
Pages: 285
Price: US$ 3,218.00 (Single User License)
ID: G2AF616621B0EN

Abstracts

Global Small Molecule Targeted Cancer Therapy Market is valued approximately at USD 83.41 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 9.50% over the forecast period 2024-2032. Targeted cancer therapies based on small molecules have revolutionized the oncology landscape, allowing for the inhibition of specific molecular pathways crucial to cancer cell survival, proliferation, and metastasis. Unlike conventional chemotherapies, these therapies are designed to selectively block enzymes and receptors implicated in oncogenic processes. As the era of precision medicine takes hold, the increasing adoption of biomarker-driven treatment regimens and the growing pipeline of small molecule inhibitors are profoundly reshaping oncology care.

The market's upward trajectory is fueled by rising cancer incidence globally, the unmet need for more effective and less toxic therapies, and advances in high-throughput screening technologies. Pharmaceutical companies are intensifying R&D efforts to develop small molecule tyrosine kinase inhibitors (TKIs), proteasome inhibitors, and CDK inhibitors, all of which offer better patient outcomes and disease progression

+357 96 030922
info@marketpublishers.com

control. In parallel, small molecule drug conjugates are gaining traction for their unique ability to combine targeted therapy with cytotoxic payloads, further enhancing the therapeutic window. Despite promising outcomes, access disparities and pricing concerns remain critical factors requiring strategic navigation by stakeholders.

Monoclonal antibodies also continue to augment this treatment ecosystem, particularly with innovations in humanized and chimeric antibody engineering. Fully human monoclonal antibodies are now increasingly being deployed in combination with small molecules, creating synergistic effects that improve therapeutic efficacy. This multidisciplinary treatment approach is reshaping the standard of care across multiple cancer types such as breast cancer, leukemia, and lung cancer, where small molecule inhibitors have shown pronounced success.

However, several roadblocks must be overcome. Development costs are considerable due to lengthy clinical trial requirements and complex regulatory pathways. Additionally, tumor heterogeneity and acquired resistance mechanisms often necessitate combination therapies or next-gen molecule modifications. Even so, these challenges have driven a surge in companion diagnostics and patient stratification techniques, thereby fostering more personalized and data-informed treatment plans.

Regionally, North America currently leads the global market, underpinned by robust biopharmaceutical infrastructure, early adoption of breakthrough therapies, and high healthcare spending. Europe follows closely, benefiting from strong academic-industry collaboration and regulatory incentives. Meanwhile, Asia Pacific is expected to witness the highest growth rate during the forecast period due to expanding cancer care awareness, growing research investments, and rising healthcare infrastructure in emerging economies such as China and India.

Major market player included in this report are:

Pfizer Inc.

Novartis AG

Bristol-Myers Squibb Company

AstraZeneca plc

F. Hoffmann-La Roche Ltd

+357 96 030922
info@marketpublishers.com

Amgen Inc.

Eli Lilly and Company

Merck & Co., Inc.

AbbVie Inc.

Johnson & Johnson

Bayer AG

Takeda Pharmaceutical Company Limited

Daiichi Sankyo Company, Limited

Exelixis, Inc.

Seagen Inc.

The detailed segments and sub-segment of the market are explained below:

By Type

Small Molecule Drug Conjugates

Small Molecules

Small Molecule Cyclin-Dependent Kinase Inhibitor

Small Molecule Proteasome Inhibitor

Small Molecule Tyrosine Kinase Inhibitor

+357 96 030922
info@marketpublishers.com

By Monoclonal Antibodies

- Fully Human Antibody
- Chimeric Monoclonal Antibody
- Humanized Monoclonal Antibody

By Region:

North America

- U.S.
- Canada

Europe

- UK
- Germany
- France
- Spain
- Italy
- ROE

Asia Pacific

- China

+357 96 030922
info@marketpublishers.com

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

+357 96 030922
info@marketpublishers.com

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

Pfizer Inc.

Novartis AG

Bristol-Myers Squibb Company

AstraZeneca plc

F. Hoffmann-La Roche Ltd

Amgen Inc.

Eli Lilly and Company

Merck & Co., Inc.

AbbVie Inc.

Johnson & Johnson

Bayer AG

+357 96 030922
info@marketpublishers.com

Takeda Pharmaceutical Company Limited

Daiichi Sankyo Company, Limited

Exelixis, Inc.

Seagen Inc.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

MARKET DYNAMICS

CHAPTER 4. GLOBAL SMALL MOLECULE TARGETED CANCER THERAPY MARKET INDUSTRY ANALYSIS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 8. COMPETITIVE INTELLIGENCE

+357 96 030922
info@marketpublishers.com

CHAPTER 9. RESEARCH PROCESS

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Small Molecule Targeted Cancer Therapy Market Size study, by Type (Small Molecule Drug Conjugates, Small Molecules (Small Molecule Cyclin-Dependent Kinase Inhibitor, Small Molecule Proteasome Inhibitor, Small Molecule Tyrosine Kinase Inhibitor)), by Monoclonal Antibodies (Fully Human Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody) and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G2AF616621B0EN.html

Price: US$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G2AF616621B0EN.html